In vitro immune function after vaccination with an inactivated, gp120- depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides

Vaccine

Volumn 18, Issue 11-12, 2000, Pages 1081-1087

  Moss, Ronald B ^a   Diveley, Jocelyn ^a   Jensen, Fred ^a   Carlo, Dennis J ^a  

^a Orchestra Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FREUND ADJUVANT; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; OLIGODEOXYNUCLEOTIDE; RANTES;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; INFECTION RESISTANCE; INTRADERMAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION; VIRUS RESISTANCE;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; DINUCLEOSIDE PHOSPHATES; HIV ANTIBODIES; HIV ANTIGENS; HIV CORE PROTEIN P24; HIV-1; INTERFERON TYPE II; LYMPH NODES; OLIGODEOXYRIBONUCLEOTIDES; RANTES; RATS; RATS, INBRED LEW; VACCINATION; VACCINES, INACTIVATED;

EID: 0033990194     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00368-0     Document Type: Article

References (16)

1. Pitcher C.J., Quittner C., Peterson D.M., Connors M., Koup R.A., Maino V.C., Picker L.J. HIV-1-specific CD4+T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nature Med. 5:1999;518-525.
2. Cho B.K., Wang C., Sugawa S., Eisen H.N., Chen J. Functional differences between memory and naïve CD8 T cells. Proc. Natl. Acad. Sci. USA. 96:1999;2976-2981.
3. Shearer G.M., Clerici M. Protective immunity against HIV infection: has nature done the experiment for us? Immunology Today. 17:(1):1996;21-24.
4. Stranford S.A., Skurnick J., Louria D., Osmond D., Chang S.Y., Sninsky J., Ferrari G., Weinhold K., Lindquist C., Levy J.A. Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response. Proc. Natl. Acad. Sci. USA. 96:(3):1999;1030.
5. Roman M., Martin-Orozco E., Goodman J.S., Nguyen M-D., Sato Y., Ronaghy A., Kornbluth R.S., Richman D.D., Carson D.A., Raz E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nature Med. 3:(8):1998;849-854.
6. Moldoveanu Z., Love-Homan L., Huang W.Q., Krieg A.M. CpG DNA. A novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine. 16:(11/12):1998;1216-1224.
7. Choi D.J., Dub S., Spicer T.P., Slade H.B., Jensen F.C., Poiesz B.J. Sequence Note: HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant. AIDS Res. and Human Retrovirus. 13:(4):1997;357-361.
8. Prior C., Bay P., Ebert B., Gore R., Hold J., Irish T., Jensen F., Leone C., Mitschelen J., Sitglitz M., Tarr C., Trauger R.J., Weber D., Hrinda M. Process development for the manufacture of inactivated HIV-1. Pharm. Tech. 19:(4):1995;30-52.
9. Moss R.B., Trauger R.J., Giermakowska W.K., Turner J.L., Wallace M.R., Jensen F.C., Richieri S.P., Ferre F., Daigle A.E., Duffy C., Theofan G., Carlo D.J. Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on β-chemokine and cytokine production in subjects with HIV-1 infection. J. Acquired Immune Deficiency Syndromes and Human Retrovirology. 14:1997;343-350.
10. Moss R.B., Wallace M.R., Lanza P., Giermakowska W., Jensen F.C., Theofan G., Chamberlin C., Richieri S.P., Carlo D.J. In vitro p24 antigen-stimulated lymphocyte proliferation and β-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune). Clinical and Diagnostic Laboratory Immunology. 5:(3):1998;308-312.
11. Moss R.B. T Helper immune responses in REMUNE immunized subjects. Proceedings of the HIV Vaccine Development; Global, Regional, and Thailand Update, Bangkok, Thailand, March 15-19. 1999.
12. ™) in human immunodeficiency virus type-1 seropositive subjects. Viral Immunology. 10:(4):1997;221-228.
13. Valentine F., DeGruttola V. Abstract 346. Proceedings of the Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, January 31-February 4. 1999.
14. Zagury D., Lachgar A., Chams V., Fall L.S., Bernard J., Zagury J.F., Bizzini B., Gringeri A., Santagostino E., Rappaport J., Feldman M., O'Brien S.J., Burny A., Gallo R.C. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc. Natl. Acad. Sci. USA. 95:(7):1998;3857-3861.
15. Sei S, Sandelli SL, Theofan G, Ratto-Kim S, Kumagai M, Loomis-Price LD, Cox JH, Jaroskinski P, Walsek CM, Brouwers P, Venzon DJ, Xu J, Pizzo PA, Moss RB, Robb ML, Wood LV. Preliminary evaluation of HIV-1 Immunogen in children with human immunodeficiency virus type 1 infection. J Infect Dis 1999;180:626-40.
16. Chu R.S., Targoni O.S., Kreig A.M., Lehmann P.V., Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186:(10):1997;1623-1631.